title: Detection of phosphorylated insulin receptor in colorectal adenoma and adenocarcinoma: implications for prognosis and clinical outcome.
abstract: Colorectal carcinoma remains among the most frequent causes of cancer death. Besides the well-known genetic predisposition, a key role in colorectal adenoma and adenocarcinoma etio-pathogenesis, mainly in sporadic cases, is played by definite risk factors, such as obesity, type 2 diabetes, insulin resistance, hyper-insulinemia, and insulin therapy. These epidemiological data motivated us to determine, by means of immunohistochemistry, the amount of activated (phosphorylated) insulin receptor in archival samples from 22 colorectal adenoma and 117 adenocarcinoma patients, with the objective to estimate the role of this factor in colorectal epithelium transformation and cancer progression. Statistical analysis of the results clearly showed that positive staining for phosphorylated insulin receptor was significantly more frequent in adenomas than adenocarcinomas (P < 0.0001) and, within the adenocarcinoma cohort, it was more frequent in low-grade tumors (P = 0.005). In adenomas, staining was exclusively cytoplasmic, while in adenocarcinomas it was cytoplasmic and/or nuclear (P < 0.0001). Interestingly, disease-free survival in colorectal adenocarcinoma patients pointed out a significantly better prognosis for those bearing a positive staining for phosphorylated insulin receptor (P = 0.02). From these data, we can argue that activated insulin receptor plays a fundamental role at the early stages of tumorigenesis, where late stages could be characterized by a shift toward more active oncogenic drivers. Determining the amount of phosphorylated insulin receptor could thus represent a novel prognostic/predictive tool in colorectal adenocarcinoma patients.
authors.affiliation: Department of Experimental Oncology, Regina Elena National Cancer Institute, IRCCS, Rome, Italy.
authors.forename: Claudia
authors.initials: C
authors.lastname: Abbruzzese
authors.forename: Maria Grazia
authors.initials: MG
authors.lastname: Diodoro
authors.forename: Isabella
authors.initials: I
authors.lastname: Sperduti
authors.forename: Anna Maria
authors.initials: AM
authors.lastname: Mileo
authors.forename: Giada
authors.initials: G
authors.lastname: Pattaro
authors.forename: Laura
authors.initials: L
authors.lastname: De Salvo
authors.forename: Maurizio
authors.initials: M
authors.lastname: Cosimelli
authors.forename: Nicola
authors.initials: N
authors.lastname: Perrotti
authors.forename: Marco G
authors.initials: MG
authors.lastname: Paggi
mesh_terms: D011125:Adenomatous Polyposis Coli / Q000235:genetics* / Q000473:pathology / Q000628:therapy*; D000328:Adult; D002471:Cell Transformation, Neoplastic / Q000235:genetics / Q000473:pathology; D018572:Disease-Free Survival; D045325:HCT116 Cells; D006801:Humans; D060787:Neoplasm Grading; D010766:Phosphorylation; D011379:Prognosis; D011972:Receptor, Insulin / Q000302:isolation & purification / Q000378:metabolism*; D016896:Treatment Outcome
chemical_list: D011972:Receptor, Insulin